Loading...
Docoh

Burzynski Research Institute (BZYR)

Burzynski Research Institute, Inc. (the “Company”) was incorporated under the laws of the State of Delaware in 1984 in order to engage in the research, production, marketing, promotion and sale of certain medical chemical compounds composed of growth-inhibiting peptides, amino acid derivatives and organic acids which are known under the trade name “Antineoplastons.” The Company believes Antineoplastons are useful in the treatment of human cancer and is currently reviewing data of its Phase II clinical trials of Antineoplastons relating to the treatment of various cancers. Antineoplastons have not been approved for sale or use by the Food and Drug Administration of the United States Department of Health and Human Services (“FDA”) or anywhere in the world. In the event Antineoplastons receive such approval and are registered in the United States, Canada, or Mexico, of which there can be no assurance, the Company will commence commercial operations, which shall include the production, marketing, promotion and sale of Antineoplastons in the United States, Canada, or Mexico. In 2004, the FDA approved the designation of Antineoplastons as an “orphan drug” under the Orphan Drug Act of 1983. See “Orphan Drug Designation” below for a detailed description of this designation and its meaning. The Company currently provides Antineoplastons solely for use by Stanislaw R. Burzynski, M.D., Ph.D. (“Dr. Burzynski”) in clinical research.

Calendar

14 Jul 22
9 Aug 22
28 Feb 23
Quarter (USD) May 22 Feb 22 Nov 21 Aug 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Feb 22 Feb 21 Feb 20 Feb 19
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Cash burn rate (est.) Burn method: Change in cash Burn method: Operating income Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 4.77K 4.77K 4.77K 4.77K 4.77K 4.77K
Cash burn (monthly) (no burn) (no burn) 77.25K 74.34K 13.04K 23.32K
Cash used (since last report) n/a n/a 178.42K 171.72K 30.13K 53.86K
Cash remaining n/a n/a -173.66K -166.95K -25.36K -49.09K
Runway (months of cash) n/a n/a -2.2 -2.2 -1.9 -2.1

Beta Read what these cash burn values mean

Financial report summary

?
Management Discussion
  • Research and development costs were approximately $167,000 and $232,000 for the three months ended May 31, 2022 and 2021, respectively. The decrease of $65,000 or 28% was due to a decrease in personnel costs of $40,000, consulting and quality control costs of $4,000, facility and equipment costs of $20,000 and materials costs of $1,000, as a result of a reduction of requirements imposed by the Food and Drug Administration.
  • General and administrative expenses were approximately $64,000 and $84,000 for the three months ended May 31, 2022 and 2021, respectively. The decrease of $20,000 or 24% was due to an decrease in legal and other professional costs of $21,000, offset by an increase in other costs of $1,000 as a result of a decrease in requests from regulatory agencies.
  • The Company had net losses of approximately $232,000 and $316,000 for the three months ended May 31, 2022 and 2021, respectively. The decrease in the net loss from 2021 to 2022 is primarily due to an overall decrease in research and development costs and general and administrative expenses of the Company as described above.

Content analysis

?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
8th grade Avg
New words: temporarily
Registration and prospectus
No filings
Proxies
No filings